RBC Capital analyst Brian Abrahams downgraded Gilead Sciences to Sector Perform from Outperform with an unchanged price target of $87.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5
- Biotech Alert: Searches spiking for these stocks today
- Opco reveals three biotech stocks that will outperform in 2023
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
- Kite says Yescarta now approved in Japan for initial treatment